Nonclinical development of RNA cancer vaccines: proof-of-concept testing, safety study design, and future prospects

RNA-based vaccines are nascent technology currently in development for the treatment of multiple types of cancer. Prior to administration in a clinical trial, nonclinical testing of RNA-based vaccines is required to evaluate activity and characterize safety. This article will discuss: 

1. Example types of mRNA cancer vaccines;
2. Commonly used delivery methods for RNAs;
3. Nonclinical approaches for evaluating activity;
4. Considerations for evaluating safety; and
5. Future prospects for RNA cancer therapeutics.

Please enter your email to access content Read now